N/A N=20 Basic Science

Protection Against Insulin Resistance in Obesity

Obesity · Insulin Resistance

Bottom Line

View on ClinicalTrials.gov: NCT02717832 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

May 2022

Primary outcome: Primary: Insulin Sensitivity — 273; 817 nmol/kg FFM/min /(µU/mL Insulin)

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: hyperinsulinemic-euglycemic clamp (Drug)
Age: Adult · 18+ yrs
Sex: All
Sponsor: University of Michigan
Primary completion: Aug 2019

Outcome Measures

Outcome	Result	p-value
PRIMARY Insulin Sensitivity	273; 817	—
SECONDARY Resting Metabolic Rate	1509; 1325	—

Summary

The overall goal of this project is to identify factors that "protect" some obese adults from becoming insulin resistant. Identifying mechanisms that help protect some obese adults from developing insulin resistance could lead to novel, targeted therapeutic and/or preventative strategies for obese adults who are insulin resistant.

Eligibility Criteria

Inclusion Criteria

Body mass index [BMI]: 30-40 kg/m2
Age: 18-45 years
All women must be pre-menopausal
Non-exerciser: no regularly planned exercise/physical activity

Exclusion Criteria

Weight instability ≥ ±3kg ≥ 6 months
Medications known to affect lipid and/or glucose metabolism
Pregnancy or actively breast feeding

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02717832). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.